Horizon Therapeutics plc announced results of a retrospective analysis that showed Uplizna appeared to offer durable efficacy and a favorable safety profile for African American patients with neuromyelitis optica spectrum disorder.
Researchers presented these data at the World Congress on Controversies in Neurology.
“Neuromyelitis optica spectrum disorder (NMOSD) is a challenging B-cell mediated disease that disproportionately affects non-white populations, including Black or African American individuals, making it valuable to have clinical trial data and subsequent analyses that are